First in Human Study of SIM0610 in Solid Tumors

Key facts

Sponsor

Jiangsu Simcere Pharmaceutical Co., Ltd.

Intervention

SIM0610 for Injection(drug)

Enrollment

260 enrolled

Eligibility

18 years · All sexes

Timeline

2026 – 2029

Study locations (7)

• Chongqing Cancer Hospital, Chongqing, Chongqing Municipality, China
• Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
• the First Hospital of China Medical University, Shenyang, Liaoning, China
• The Affiliated Cancer Hospital of Shandong First Medical University& Shan Dong Cancer Hospital, Jinan, Shandong, China
• Shanghai East Hospital, Shanghai, Shanghai Municipality, China
• Shanghai Pulmonary Hospital, Shanghai, Shanghai Municipality, China
• Zhongshan Hospital, Fudan University, Shanghai, Shanghai Municipality, China

Collaborators

Shanghai Xianwei Medical Technology Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Small cell lung cancer

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT06694454
  Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
  National Cancer Institute (NCI)
• RECRUITINGNANCT07398599
  Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
  Second Affiliated Hospital of Nanchang University
• RECRUITINGPHASE1, PHASE2NCT07480213
  Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
  Beijing Biotech
• RECRUITINGPHASE1, PHASE2NCT07227597
  A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
  Merck Sharp & Dohme LLC
• RECRUITINGNANCT07161310
  Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors
  Goethe University
• RECRUITINGPHASE2NCT07304739
  Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
  Tianjin Medical University Cancer Institute and Hospital
• RECRUITINGPHASE3NCT07185997
  Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
  ArriVent BioPharma, Inc.
• RECRUITINGPHASE1, PHASE2NCT06956690
  A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
  Hummingbird Bioscience

See all trials for Small cell lung cancer →